Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.55 |
| ▸ | MBNL1 | Q9NR56 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | C1R | P00736 | 1/20 | 0.45 |
| ▸ | DHODH | Q02127 | 8/20 | 0.45 |
| ▸ | DHFR | P00374 | 1/20 | 0.43 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TACR3 | P29371 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13063652 | 0.88 | ADORA2A (0.57) | ADORA2AMBNL1KMT2AC1RDHODH | |
| SCHEMBL2123544 | 0.84 | ADORA2A (0.53) | ADORA2AMBNL1KMT2AC1RDHODH | |
| SCHEMBL2123690 | 0.84 | ADORA2A (0.53) | ADORA2AMBNL1KMT2AC1RDHODH | |
| SCHEMBL2123351 | 0.79 | ALOX5AP (0.45) | KMT2ADHODHPIK3CA | |
| SCHEMBL27883214 | 0.79 | KMT2A (0.40) | ADORA2AMBNL1KMT2ADHODHMAPT | |
| SCHEMBL1758144 | 0.77 | ADORA2A (0.55) | ADORA2AMBNL1KMT2AC1RMAPT | |
| SCHEMBL13063627 | 0.77 | MBNL1 (0.55) | ADORA2AMBNL1DHODHMAPTPIK3CA | |
| SCHEMBL1758166 | 0.77 | ADORA2A (0.55) | ADORA2AMBNL1KMT2AC1RDHODH | |
| SCHEMBL13063898 | 0.77 | MBNL1 (0.55) | ADORA2AMBNL1DHODHDHFRALKBH5 | |
| SCHEMBL27866881 | 0.76 | HSD11B1 (0.49) | KMT2ADHODHMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765940-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120094972-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094972-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | ADORA2A 1268/4885MBNL1 1806/4885KMT2A 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.